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ABSTRACT
Background and Objectives: Pseudomonas aeruginosa is one of the most important causative agents of nosocomial 
infections especially in ICU and burn units. P. aeruginosa infections are normally difficult to eradicate due to acquired 
resistance to many antibiotics. Recent appearance of carbapenem resistant P. aeruginosa isolates is considered a major 
healthcare problem. The present study was conducted to detect class 1 integron and antibiotic susceptibility profiles of 
imipenem-sensitive and resistant clinical isolates of P. aeruginosa. 
Materials and Methods: Antibiotic susceptibility profiles and minimum inhibitory concentration against imipenem was 
studied in 160 clinical isolates of P. aeruginosa by disk agar diffusion method and Etest, respectively. Detection of class 
1 integron was performed by the PCR method. Demographic and microbiological data were compared between imipenem 
susceptible and non-susceptible isolates by the SPSS software.  
Results: PCR results showed that 90 (56.3%) of P. aeruginosa isolates carried class 1 integron. Antibiotic susceptibility 
results revealed that 93 (58.1%) were susceptible and 67 (41.9%) were non-susceptible to imipenem. Comparison of 
antibiotic susceptibility patterns showed high level of drug resistance among imipenem non-susceptible isolates. We found 
that MDR phenotype, presence of class 1 integron and hospitalization in ICU and burn units were significantly associated 
with imipenem non-susceptible isolates.
Conclusion: The high frequency of imipenem resistance was seen among our P. aeruginosa isolates. Since carbapenems are 
considered as the last drugs used for treatment of P. aeruginosa infections, it is crucial to screen imipenem non-susceptible 
isolates in infection control and optimal therapy. 
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INTRODUCTION
Pseudomonas aeruginosa is a ubiquitous Gram-
negative bacterium causing various types of infections 
and frequently isolated from clinical specimens (1). 
The  range  of  diseases  caused  by  this  bacterium 
varies  from  superficial  skin  infections  to  serious 
systemic infections such as fulminant sepsis (2). P. 
aeruginosa is the second most common causative 
agent of hospital-acquired pneumonia, healthcare-
associated  pneumonia  and  ventilator-associated 
pneumonia.  P.  aeruginosa  is  also  an  important 
pathogen in immunocompromised patients, such as 
patients suffering from AIDS, cancer, burn wounds 
and cystic fibrosis (CF) (3). Infections caused by P. 
aeruginosa are often difficult to eradicate because 
it  requires  minimal  nutrition  and  can  tolerate  a 
wide range of temperatures. Also, it is resistant to 
many antibiotics, disinfections and has the ability to 
acquire resistance (4). 
Carbapenem  antibiotics  remain  as  the  last  the     
rapeutic  option  for  treatment  of  serious  infections 
caused  by  P.  aeruginosa.  Recently,  emerging 
antimicrobial resistance to most classes of antibiotics, 
including  carbapenems,  resulted  in  developing 
multidrug resistant  P. aeruginosa isolates (isolates 
resistant to at least 3 different classes of antibiotics) (5). 
Emergence of multiple drug resistance P. aeruginosa 
appeared  as  a  great  problem  in  clinical  settings 
due  to  limited  therapeutic  options  (6,  7).  Various 
mechanisms are involved in antimicrobial resistance 
in  P.  aeruginosa  including  intrinsic  resistance  and 
gene acquisition by horizontal transfer mediated by 
mobile genetic elements., Plasmids, transposons and 
integrons are vehicles and structures for mobilization, 
acquisition  and  spreading  of  resistance  genes  (8). 
Integrons are common gene capture and expression 
systems that incorporate ORFs (open reading frame) 
and convert them into functional genes. The essential 
components of an integron include the integrase gene 
(int I), the attachment site (att I) and the promoter, 
which  promotes  the  expression  of  any  suitably 
integrated gene (s) (9). 
Multiple classes of integrons have been identified 
according to their distinct integrase genes in Gram-
negative  bacteria.  Class  1  integrons  are  the  most   
prevalent  in  clinical  isolates  and  carry  single  or 
multiple  gene  cassettes.  Genes  carried  by  integrons 
encode for various antibiotic resistance mechanisms, 
including resistance to aminoglycosides, sulphonamids, 
β-lactams, macrolides, chloramphenicol, antiseptics 
and  disinfectants.  In  case  of  β-lactamases,  integron-
born  gene  cassettes  have  been  found  mainly  in  P. 
aeruginosa,  Acinetobacter  baumannii  and  various 
species of Enterobacteriaceae (10), but its prevalence 
is variable in different parts of the world (8, 11- 13). 
The  present  study  was  designed  to  investigate  the 
prevalence  of  class  1  integron  and  antimicrobial 
susceptibility profiles of imipenem susceptible and 
imipenem non-susceptible isolates of P. aeruginosa 
at a University Hospital in Orumieh, Iran. 
MATeRIALS  AND  MeThODS
Bacterial isolates. A total of 160 non-duplicate 
clinical  isolates  of  P.  aeruginosa  isolates  were 
collected  from  Orumieh  Imam  Hospital  between 
August  2007  and  August  2008.  A  questionnaire 
was  used  for  recording  patients’  demographic 
and  clinical  data.  Bacterial  isolates  were  recovered 
from  different  clinical  samples  such  as;  bronchial 
fluid,  blood  culture,  catheter,  cerebrospinal  fluid, 
ear,  pleural  fluid,  sputum,  urine  and  wound.  All 
isolates were identified as P. aeruginosa by using 
standard microbiological tests such as; Gram stain, 
oxidase test, growth at 42°C, growth on Cetrimide 
agar medium (Liofilchem, Italy), O/F (Oxidation-
Fermentation) test and pigment production (14).
Antimicrobial Susceptibility testing. Antimicrobial 
susceptibility testing was performed by the disk agar 
diffusion method according to Clinical and Laboratory 
Standards Institute (CLSI) recommendations (15). 
The following antimicrobial disks (Mast Co. UK) 
were  used  for  antimicrobial  susceptibility  testing; 
imipenem (10 µg), meropenem (30 µg), aztreonam 
(10  µg),  cefepime  (30  µg),  ceftazidime  (30  µg), 
ceftriaxone (30 µg), cephalexin (10 µg), amikacin 
(30 µg), gentamicin (10 µg), ciprofloxacin (30 µg), 
norfloxacin (10 µg), piperacillin/tazobactam (100 µg).   
P.  aeruginosa  ATCC  27853  was  used  as  quality   
control  in  each  run  of  antimicrobial  susceptibility 
testing. 
Determination of minimum inhibitory concentration.  
Minimum  inhibitory  concentrations  (MICs)  of 
imipenem susceptible and imipenem non-susceptible 
isolates of P. aeruginosa were determined by using 
Etest strips (BioMerieux AB Biodisk Solna-Sweden). 
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overnight culture of bacterial isolates were used for 
preparation of 0.5 McFarland turbidity standard. Then 
bacterial suspension was inoculated onto the Muller-
Hinton  agar  (Merck,  Germany)  plates  by  using  a 
cotton swab and spread all over the plate. Imipenem 
Etest strip was laid on the surface of Muller-Hinton 
agar plate in a position that the whole length of strip 
be in complete contact with the agar surface. After 
incubation at 37°C for 16-18 hours, the MIC values 
were read where the inhibition ellipses intersect the 
Etest strip. P. aeruginosa ATCC 27853 was used as a 
control for antimicrobial susceptibility testing.
˺ 
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Figure 1: Specimen sources of imipenem susceptible and non-susceptible P. aeruginosa isolates
Fig. 1. Specimen sources of imipenem susceptible and non-susceptible P. aeruginosa isolates.
Antibiotic
Imipenem susceptible (n=93) Imipenem non-susceptible (n=67)
Sensitive Intermediate Resistant Sensitive Intermediate Resistant
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Amikacin 73 (78.5) 1 (1.1) 19 (20.4) 6 (9) - - 61 (91)
Aztreonam 40 (43) 24 (25.8) 29 (31.2) 3 (4.5) 3 (4.5) 61 (91)
Ceftazidime 68 (73.1) 2 (2.1) 23 (24.7) 8 (11.9) 3 (4.5) 56 (83.6)
Ciprofloxacin 58 (62.4) 2 (2.1) 33 (35.5) 5 (7.5) 2 (3) 60 (89.5)
Cephalexin 35 (37.6) 2 (2.1) 56 (60.2) 5 (7.5) 1 (1.5) 61 (91)
Cefepime  65 (69.9) 2 (2.1) 26 (28) 4 (6) 2 (3) 61 (91)
Ceftriaxon 14 (15) 6 (6.5) 73 (78.5) 3 (4.5) 3 (4.5) 61 (91)
Cefotaxime 35 (37.6) 1 (1.1) 57 (61.3) 3 (4.5) 9 (13.4) 55 (82.1)
Gentamicin 58 (62.4) 2 (2.1) 33 (35.5) 4 (6) 2 (3) 61 (91)
Meropenem  87 (93.4) 5 (5.4) 1 (1.2) 4 (6) 1 (1.5) 62 (92.5)
Norfloxacin 48 (51.6) 4 (4.3) 41 (44.1) 7 (10.4) 4 (6) 56 (83.6)
Piperacillin/tazobactam 76 (81.7) 7 (7.5) 10 (10.8) 4 (6) 2 (3) 61 (91)
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DNA extraction. DNA extraction was performed 
by simple boiling method. In practice, 2-3 colonies 
of overnight culture of P. aeruginosa isolates were 
suspended in 400 µl of 1× TE buffer (10 mM Tris, 1m 
M EDTA) by vortexing. The suspension was heated in 
a boiling bath at 95°C for 10 min. Then cellular debris 
was removed by centrifugation at ×12000 RPM for 
10 min. One μl of supernatant was used as template 
DNA in PCR reactions. 
Class 1 integron PCR. The  integrase  gene  (int 
I)  was  amplified  in  PCR  reaction  for  detection 
of  class  1  integron  using  primers:  Int1-F: 
5-GGTGTGGCGGGCTTCGTG-3  and  Int1-R: 
5-GCATCCTCGGTTTTCTGG-3 (16). PCR master 
mix component was as follows; 10× PCR buffer in 
final concentration of 1×, MgCl2 (50 mM) in a final 
concentration of 1.5 mM, dNTP Mix, 10 mM in a 
final concentration of 0.2 mM, forward and reverse 
primers  in  a  final  concentration  of  0.4  μM.  PCR 
amplification was performed in a total volume of 25 
μl (24 μl of PCR master mix plus 1 μl of template 
DNA).  P.  aeruginosa  PA66  (VIM  positive)  and 
Serratia marcescens CI 10-4-9 (IMP positive) isolates 
were used as positive controls for class 1 integron.  
  PCR amplification condition was as follows: initial 
denaturation at 95°C for 4 min followed by 35 cycles 
of 60 seconds at 94°C (denaturation), 60 seconds at 
62°C (annealing) and 45 seconds at 72°C (extension) 
with a final extension at 72°C for 7 minutes. PCR 
products were analyzed by electrophoresis in 1.2% 
agarose gel in a TAE buffer at 90 volts alongside 
with 1 Kbp DNA ladder. Then gels were stained in 
ethidium bromide solution for 15 minutes and finally 
visualized in gel documentation system. 
Statistical  analysis.  For  statistical  analysis,  the 
isolates  were  divided  into  two  groups;  imipenem 
susceptible  isolates  and  imipenem  non-susceptible 
isolates. Descriptive statistics including frequencies, 
cross-tabulation  of  microbiological,  clinical  and 
demographic  data  were  analyzed  using  SPSS 
statistical software (version 16.0). The χ2 test, or the 
Fishers’ exact test, when appropriate, was used in a 
univariate analysis to assess the differences between 
two groups of isolates, p values less than 0.05 were 
considered statistically significant.
ReSULTS
  During the study period, a total of 160 isolates of 
P.  aeruginosa  were  collected  from  different  wards 
of Orumieh Imam Hospital which is a tertiary care 
center of Orumieh Medical Sciences University. One 
hundred and forty six (91.2%) of isolates were obtained 
from hospitalized patients and 14 (8.8%) belonged 
to  out-patients.  Frequency  of  isolates  according  to 
hospital wards were as follows; burn unit 52 (32.5%), 
ICU  wards  32  (20%),  surgery  wards  18  (11.2%), 
nephrology ward 14 (8.8%), internal medicine wards 
13 (8.1%), urology ward 7 (4.4%), kidney transplant 
unit 5 (3.1%), oncology ward 5 (3.1%) and 14 (8.8%) 
were isolated from out-patients. 
Specimen sources with regard to the two categories 
of imipenem susceptible and non-susceptible isolates 
have  been  demonstrated  in  Fig.  1.  Mean  age  of 
patients was 42 ± 25.1 (rang: 1- 111). Ninety-seven 
(60.6%) patients were males and 63 (39.4%) patients 
were females (male to female ratio 1.54:1). 
  Antibiotic  susceptibility  results  showed  that  93 
(58.1%) of P. aeruginosa isolates were sensitive to 
imipenem, 61 (38.1%) were resistant and 6 (3.8%) 
of isolates showed intermediate resistance. Antibiotic 
susceptibility testing showed that overall rate of drug 
resistance among imipenem non-susceptible isolates 
was  higher  than  imipenem  susceptible  isolates.     
These  differences  were  statistically  significant 
(Table 1). Determination of MIC against imipenem 
by Etest method revealed that Mean MIC among the 
imipenem non- susceptible isolates was 31.43 mg/L 
while this value for imipenem susceptible isolates was 
˻ 
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Figure 2: PCR amplification of Class 1 integron gene in clinical P. aeruginosa isolated from 
Imam Hospital of Orumieh, Iran. 
                                Lane 1: positive isolate                        
                                   Lane 2: positive isolate
                                   Lane 3-6: positive isolate 
                                   Lane 7: positive isolate
                                   Lane 8, 9: positive control isolates (VIM and IMP type positive isolates) 
                                   Lane 10: 1 Kbp DNA ladder 
                                   Lane 11: negative control                           
Fig. 2. PCR  amplification  of  Class  1  integron  gene  in 
clinical  P.  aeruginosa  isolated  from  Imam  Hospital  of 
Orumieh, Iran.
Lanes; 1: positive isolate, 2: positive isolate, 3-6: positive 
isolate, 7: positive isolate, 8, 9: positive control isolates 
(VIM  and  IMP  type  positive  isolates),  10:  1  Kbp  DNA 
ladder, 11: negative control. 
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2.86 mg/L. 
  Analysis  of  patients’  demographics  and 
microbiological data between imipenem susceptible 
and  non-susceptible  isolates  by  SPSS  software 
showed that majority of imipenem non-susceptible 
isolates belonged to hospitalized patients harboring 
class 1 integron and were MDR P. aeruginosa. In 
addition, we found that hospitalization in burn units 
and  ICU  wards  had  significant  association  with 
imipenem non-susceptible isolates (p < 0.05). 
    Investigation of class 1 integron by PCR method 
indicates that 90 (56.3%) of P. aeruginosa isolates 
carried  this  gene  (Fig.  2).  Frequency  of  class  1 
integron were 29 (31.2%) and 61 (91.0%) in imipenem 
susceptible  and  imipenem  non-susceptible  isolates, 
respectively. Other factors associated with imipenem 
susceptibility among P. aeruginosa isolates have been 
presented in Table 2. 
DISCUSSION
  P. aeruginosa is one of the most common causes 
of life-threatening and difficult-to-treat nosocomial 
infections  (17).  Resistance  to  antimicrobial  agents 
appeared as a great problem in clinical settings.  Recently 
emerging  carbapenem  resistance  in  P.  aeruginosa 
isolates have limited therapeutic options for treatment 
of  MDR  P.  aeruginosa  which  are  considered  as  the 
last line of drugs for treatment of infections caused by 
these organisms (18, 19). Different resistance associated 
encoding genes such as extended spectrum β-lactamases 
(ESBLs), which hydrolyse third and fourth generation 
cephalosporins,  and  metallo-β-lactamases  (MBLs), 
which hydrolyse carbapenems, are located in class 1 
integron structures (8). 
Since  knowledge  about,  antibiotic  susceptibility 
can help choose the appropriate treatment agents and 
Demographic, clinical and microbiological variables Imipenem susceptible  (n = 93) Imipenem non-susceptible  (n = 67) p
Demographic:
     Mean age (± SD) 1 50.74 ± 23.88 29.85 ± 21.54 < 0.001
     Gender
Female 31 (33.3%) 32 (47.8%)
0.073
Male 62 (66.7%) 35 (52.2%)
     Patients
In-patients 80 (86%) 66 (98.5%)
0.008
Out-patients 13 (14%) 1 (1.5%)
Clinical:
     Surgery  48 (51.6%) 41 (61.2%) 0.261
     Hospitalized in burn ward 2 (2.2%) 50 (74.6%) < 0.001
     Hospitalized in ICU ward 46 (49.5%) 11 (16.4%) < 0.001
     Chronic lung disease  16 (17.2%) 7 (10.4%) 0.261
     Mechanical ventilation 15 (16.1%) 9 (13.4%) 0.823
     Death during hospitalization  17 (18.3%) 16  (23.9%) 0.431
Microbiological:
     MDR P. aeruginosa 28 (30.1%)   62 (92.5%) < 0.001
     Class 1 integron gene 29 (31.2%) 61 (91%)  < 0.001
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also to control nosocomial infections, in the present 
study  we  investigated  the  antibiotic  susceptibility 
pattern, presence of class 1 integron and imipenem 
resistance  in  clinical  isolates  of  P.  aeruginosa  at 
Orumieh University Hospital.
The results of the present study showed a high level 
of  antimicrobial  resistance  among  P.  aeruginosa 
isolates. Sixty-seven (41.9%) of P. aeruginosa isolates 
were  non-susceptible  to  imipenem.  Other  studies 
in  Iran  reported  that  the  prevalence  of  imipenem 
resistance  P. aeruginosa varied from 2.9% to 61.83% 
in Tehran, the capital of Iran (20, 21). Saderi et al., 
reported that 38.28% of P. aeruginosa isolates from 
Tehran were resistant to imipenem (22), Khosravi et 
al. reported that 41% of P. aeruginosa isolates from 
burn patients in Ahwaz (located in southwest of Iran) 
showed resistant to imipenem (23).
  Comparison  of  antibiotic  susceptibility  pattern 
between imipenem susceptible and imipenem non-
susceptible isolates revealed that the resistance rate 
among imipenem non-susceptible isolates were higher 
than imipenem susceptible isolates. This difference 
was statistically significant (p < 0.05) in case of all 
tested  antibiotics  except  ceftriaxone.  Imipenem, 
meropenem  and  piperacillin/tazobactam  were  the 
most effective antibiotics respectively.  This was in 
accordance with findings of Japoni and coworkers in 
south of Iran (24).
Previous studies have shown that antibiotic resistance 
rate in clinical settings is higher which is probably 
because of wide range of antibiotic use in hospitalized 
patients. In our study, 91.25% of isolates belonged to 
the hospitalized patients from which 52.5% of isolates 
were  collected  from  ICU  and  burn  units  (19,  25). 
Furthermore,  in  our  study,  all  hospitalized  patients 
in  ICU  and  burn  units  had  a  history  of  imipenem 
administration  during  their  hospital  stay.  This  also 
was reported by Onguru et al. It seems  prior exposure 
to antibiotics remains as one of the most important 
factors for drug resistance (26). 
  Screening of P. aeruginosa isolates for class 1 integron 
revealed that there is a significant difference among 
imipenem susceptible and imipenem non-susceptible 
isolates. These data are in accordance with Fonseca 
et al. findings that reported 56.6% of imipenem non-
susceptible and 32.5% of imipenem susceptible isolates 
were positive for class 1 integron (8). Comparison of 
frequency  of  MDR  isolates  and  presence  of  class  1 
integron in two groups of isolates showed that 92.5% 
of imipenem non-susceptible isolates were MDR and 
91% were positive for class 1 integron. This could be 
explained with the fact that several studies have reported 
the presence of different resistance genes, including 
aminoglycosides, in class 1 integron (8).  
  In conclusion, the high prevalence of antimicrobial 
resistance  observed  among  P.  aeruginosa  isolates 
underlines the strict consideration in antibiotics use at 
clinical settings. Therefore, it is important to perform 
antibiotic  surveillance  programs  for  appropriate 
empirical therapy and infection control practices.   
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